Clinical Trial Update: Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating erlotinib for locally advanced or metastatic papillary renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillary Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer | Phase 2 | Status: COMPLETED